Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome

@article{Brownlee2017OpportunisticIA,
  title={Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome},
  author={W. Brownlee and J. Chataway},
  journal={Multiple Sclerosis Journal},
  year={2017},
  volume={23},
  pages={876 - 877}
}
876 journals.sagepub.com/home/msj by Merck, Biogen, Novartis, and Sanofi-Genzyme. Dr De Mercanti had travel expenses for congresses paid by Merck, Biogen, Novartis, and Sanofi-Genzyme. Dr Artusi had travel expenses for congresses paid by Merck, Biogen, Novartis, and Sanofi-Genzyme. Dr Durelli received personal compensation by Sanofi-Genzyme for participating to advisory boards, by Merck for editorial collaborations, and had travel expenses for congresses paid by Merck, Biogen, Novartis, and… Expand
20 Citations
Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management
  • 46
  • PDF
Monoclonal Antibodies for Multiple Sclerosis: An Update
  • 10
An update on cladribine for relapsing-remitting multiple sclerosis
  • 11
Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach
  • 4
  • PDF
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
  • 8
Alemtuzumab for the treatment of multiple sclerosis
  • 32
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
  • 10
  • PDF
...
1
2
...

References

SHOWING 1-8 OF 8 REFERENCES
Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
  • 57
  • PDF
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
  • 422